Business Wire

Prestamos Prima’s Viventor Sets Focus on European Fintech Market, Partners with Investment Holding Finstar Financial Group

Del

Prestamos Prima (“the Company”) has at the same time announced a significant enhancement of its product offering including new features for its European peer-to-peer lending platform, which offers low risk investments in loans supported by mortgages, adding high-yield consumer loans and a ‘Secondary Market’ to the platform.

Finstar already has a strong track record in the financial technology and consumer finance space and has established successful partnerships with fast-growing lenders across Europe. Last year it also launched its own portfolio company, Digital Finance International, with the aim of applying the most advanced technological solutions to deliver tailored consumer lending solutions globally.

Prestamos Prima’s newest product is Viventor, a peer-to-peer investing platform open to investors from all over Europe. All loans listed on the platform are secured by a 60-day Buyback Guarantee, and are 100% pre-funded. The loans are issued by Twinero and Prestamos Prima. Investors can choose from a range of low-risk loans secured by real estate mortgages that generate modest returns, and a variety of newly added short-term consumer loans that have no underlying assets, have comparatively higher levels of risk, generating returns as high as 15% per annum. Investing in Viventor is free, with a minimum deposit of just EUR 50 needed to open an account and you can invest as little as EUR 10 per loan. A ‘Secondary Market’ enables investors to sell their stakes in loans to other investors at a par, premium or discount, and exit their investment positions prematurely.

Andris Rozenbahs, COO of Viventor: “Offering short-term consumer loans on Viventor is a big step forward for us as a company. A considerable number of our investors have expressed their desire to diversify their portfolios across different loan types, seeking higher returns. Twinero is a trusted name that has been operating in Spanish market for years, building up a strong track record. We believe offering short-term loans is a great way of satisfying the demand of our investors.”

“Partnering with Finstar Financial Group is a huge advantage for us in the long term. The Finstar team consists of number of highly experienced professionals in the financial services industry and this expertise will greatly aid Viventor's development in the rapidly growing space of peer-to-peer financing and beyond.”

Nicholas Jordan, CEO of Finstar Financial Group: “We are excited about our partnership with a peer-to-peer lending platform such as Prestamos Prima’s Viventor. Finstar is always looking for innovative products in the fintech space and Prestamos Prima is a leader in the European market. We are delighted to work with the talented management team to strengthen Viventor, assist with rapid expansion of other projects and the further diversification of its portfolio.”

About Finstar

Finstar Financial Group is an international private equity group. Founded in 1996, the Group has significant experience in launching start-up projects and in restructuring and expanding of companies in selected industries. Finstar operates in financial markets, the IT and telecoms field, perfumery-cosmetic retailing and in commercial and trade real estate. The Group has under its management assets worth a total of more than $2 billion. Over the years Finstar has developed substantial operational experience which helps to implement a value-adding strategy, introducing high international standards of corporate governance, innovation, marketing and building competitive advantages, all of which are vital to create value in the long-term.

Read more about Finstar: www.finstar.com

About Prestamos Prima

Prestamos Prima has been operating in the European non-bank lending and alternative finance market since 2012. The company has gradually developed its portfolio, both in terms of loan volume and product diversity. Having established a leading position in the Spanish market, the group is aiming at international expansion in 2016 and beyond. Viventor has been nominated for the European Fintech Awards 2016.

Read more about Prestamos Prima: http://prestamosprima.com/ and
Viventor: https://www.viventor.com/

Contact information

Finstar Financial Group
Public Relations:
Larisa Shishkina / Marina Evseeva, +7 905 529 12 52
Shishkina@finstar.com / Marina.Evseeva@finstar.com
or
Prestamos Prima Group
Andris Rozenbahs, +34 935 297 780
info@prestamosprima.com
or
Instinctif Partners
David Simonson / Mark Walter, +44 20 7866 7887
David.Simonson@instinctif.com / Mark.Walter@instinctif.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45Pressemelding

VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great

Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41Pressemelding

Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d